Further studies on the ability of glucosamine and chondroitin sulphate to regulate catabolic mediators in vitro

Equine Veterinary Journal

Volumn 36, Issue 7, 2004, Pages 634-636

  Schlueter, A E ^a   Orth, M W ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

Horse; MMP 2; MMP 9; Nitric oxide; Prostaglandin E2

Indexed keywords

CHONDROITIN SULFATE; GLUCOSAMINE;

ANIMAL TISSUE; ARTICLE; CATABOLISM; CONTROLLED STUDY; NONHUMAN; OSTEOARTHRITIS;

ANIMALIA; EQUUS CABALLUS;

EID: 8644257589     PISSN: 04251644     EISSN: None     Source Type: Journal    
DOI: 10.2746/0425164044864471     Document Type: Article

References (21)

1. Bertone, A.L., Palmer, J.L. and Jones, J. (2001) Synovial fluid cytokines and eicosanoids as markers of joint disease in horses. Vet. Surg. 30, 528-538.
2. Bird, J.L., May, S. and Bayliss, M.T. (2000) Nitric oxide inhibits aggrecan degradation in explant cultures of equine articular cartilage. Equine vet. J. 32, 133-139.
3. Blanco, F.J., Ochs, R.L., Schwarz, H. and Lotz, M. (1995) Chondrocyte apoptosis induced by nitric oxide. Am. J. Pathol. 146, 75-85.
4. Brama, P.A., TeKoppele, J.M., Beekman, B., van Weeren, P.R. and Barneveld, A. (1998) Matrix metalloproteinase activity in equine synovial fluid: influence of age, osteoarthritis, and osteochondrosis. Ann. Rheum. Dis. 57, 697-699.
5. Byron, C.R., Orth, M.W., Venta, P.J., Lloyd, J.W. and Caron, J.P. (2003) Influence of glucosamine on matrix metalloproteinase expression and activity in lipopolysaccharide-stimulated equine chondrocytes. Am. J. vet. Res. 64, 666-671.
6. Canapp, S.O., McLaughlin, R.M., Hoskinson, J.J., Roush, J.K. and Butine, M.D. (1999) Scintigraphic evaluation of dogs with acute synovitis after treatment with glucosamine hydrochloride and chondroitin sulphate. Am. J. vet. Res. 60, 1552-1557.
7. Du, J. and Eddington, N. (2002) Determination of the chondroitin sulphate disaccharides in dog and horse plasma by HPLC using chondroitinase digestion, precolumn derivatization, and fluorescence detection. Anal. Biochem. 306, 252-258.
8. Fenton, J.I., Chlebek-Brown, K.A., Caron, J.P. and Orth, M.W. (2002) Effect of glucosamine on interleukin-1-conditioned articular cartilage. Equine vet. J. 34, 219-223.
9. Fenton, J.I., Chlebek-Brown, K.A., Peters, T.L., Caron, J.P. and Orth, M.W. (2000) Glucosamine HCl reduces equine articular cartilage degradation in explant culture. Osteoarthritis Cartilage 8, 258-265.
10. Fernandes, J.C., Martel-Pelletier, J. and Pelletier, J.P. (2002) The role of cytokines in osteoarthritis pathophysiology. Biorheol. 39, 237-246.
11. Frean, S.P., Bryant, C.E., Froling, I.L., Elliott, J. and Lees, P. (1997) Nitric oxide production by equine articular cells in vitro. Equine vet. J. 29, 98-102.
12. Hanson, R.R., Smalley, L.R., Huff, H.F., White, S. and Hammad, T.A. (1997) Oral treatment with a glucosamine-chondroitin sulphate compound for degenerative joint disease in horses: 25 cases. Equine Pract. 9, 16-22.
13. Kirker-Head, C.A., Chandna, V.K., Agarwal, R.K., Morris, E.A., Tidwell, A., O'Callaghan, M.W., Rand, W. and Kumar, M.S. (2000) Concentrations of substance P and prostaglandin E2 in synovial fluid of normal and abnormal joints of horses. Am. J. vet. Res. 61, 714-718.
14. Leffler, C.T., Philippi, A.F., Leffler, S.G., Mosure, J.C. and Kim, P.D. (1999) Glucosamine, chondroitin, and manganese ascorbate for degenerative joint disease of the knee or low back: a randomized, double-blind, placebo-controlled pilot study. Mil. Med. 164, 85-91.
15. Lippiello, L., Woodward, J., Karpman, R. and Hammad, T.A. (2000) In vivo chondroprotection and metabolic synergy of glucosamine and chondroitin sulphate. Clin. Orthop. 381, 229-240.
16. Moses, V.S., Hardy, J., Bertone, A.L. and Weisbrode, S.E. (2001) Effects of anti-inflammatory drugs on lipopolysaccharide-challenged and -unchallenged equine synovial explants. Am. J. vet. Res. 62, 54-60.
17. Orth, M.W., Peters, T.L. and Hawkins, J.N. (2002) Inhibition of articular cartilage degradation by glucosamine-HCl and chondroitin sulphate. Equine vet. J. 34, 224-229.
18. Pelletier, J.P., Jovanovic, D., Fernandes, J.C., Manning, P., Connor, J.R., Currie, M.G., Di-Battista, J.A. and Martel-Pelletier, J. (1998) Reduced progression of experimental osteoarthritis in vivo by selective inhibition of inducible nitric oxide synthase. Arthritis Rheum. 41, 1275-1286.
19. Reginster, J.Y., Deroisy, R., Rovati, L.C., Lee, R.L., Lejeune, E., Bruyere, O., Giacovelli, G., Henrotin, Y., Dacre, J.E. and Gossett, C. (2001) Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 357, 251-256.
20. Tung, J.T., Arnold, C.E., Alexander, L.H., Yuzbasiyan-Gurkan, V., Venta. R.I., Richardson, D.W. and Caron, J.P. (2002) Evaluation of the influence of prostaglandin E2 on recombinant equine interleukin-1beta-stimulated matrix metalloproteinases 1,3, and 13 and tissue inhibitor of matrix metalloproteinase 1 expression in equine chondrocyte cultures. Am. J. vet. Res. 63, 987-993.
21. Weinberg, J.B. (2001) Nitric oxide synthase 2 and cyclooxygenase 2 interactions in inflammation. Immunol. Res. 22, 319-341.